HC Wainwright maintains "buy" rating for Sangamo Therapeutics, whose Fabry disease therapy ST-920 sees potential approval with updated study plans and European Medicines Agency priority medicines eligibility.

HC Wainwright reiterated its "buy" rating for Sangamo Therapeutics, with a price target of $3.00. This suggests a potential upside of 284.47%. Sangamo Therapeutics stock increased 37% on updates for its Fabry disease therapy, ST-920. The FDA has advised that a study of up to 25 patients in combination with confirmatory evidence may be sufficient for approval of ST-920. The European Medicines Agency has granted priority medicines eligibility to the product, including enhanced regulatory support and scientific guidance.

February 12, 2024
4 Articles